XML 91 R68.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disaggregation of Revenue [Line Items] |  |  |
Net sales | $ 16,747 | $ 14,240 | $ 12,682
Contract with Customer, Liability [Abstract] |  |  |
Contract with Customer, Liability | 635 | 577 |
Change in Contract with Customer, Liability [Abstract] |  |  |
Contract with Customer, Liability, Revenue Recognized | 231 |  |
UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 10,210 | 8,425 | 7,632
Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 6,538 | 5,816 | 5,111
EMEA [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 3,228 | 2,856 | 2,526
APAC [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,686 | 2,400 | 2,116
Latin America and Canada [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 624 | 560 | 469
Emerging Markets [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,680 | 2,310 | 1,968
country_US excluding Other Net Sales |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 10,210 | 8,425 | 7,632
Global Endoscopy (Endo) Reporting Unit [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,687 | 2,482 | 2,221
Global Endoscopy (Endo) Reporting Unit [Member] | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,651 | 1,511 | 1,341
Global Endoscopy (Endo) Reporting Unit [Member] | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,036 | 970 | 880
Global Urology and Pelvic Health Reporting Unit [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,200 | 1,964 | 1,773
Global Urology and Pelvic Health Reporting Unit [Member] | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,557 | 1,369 | 1,257
Global Urology and Pelvic Health Reporting Unit [Member] | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 643 | 595 | 516
Global Neuromodulation (NM) Reporting Unit [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,106 | 976 | 917
Global Neuromodulation (NM) Reporting Unit [Member] | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 847 | 736 | 715
Global Neuromodulation (NM) Reporting Unit [Member] | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 259 | 240 | 202
Global Peripheral Interventions (PI) Reporting Unit [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,410 | 2,110 | 1,899
Global Peripheral Interventions (PI) Reporting Unit [Member] | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,301 | 1,135 | 1,048
Global Peripheral Interventions (PI) Reporting Unit [Member] | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,109 | 975 | 850
Interventional Cardiology Therapies | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,645 | 2,417 | 2,228
Interventional Cardiology Therapies | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 824 | 743 | 744
Interventional Cardiology Therapies | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,820 | 1,674 | 1,485
Cardiac Rhythm Management | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,279 | 2,218 | 2,100
Cardiac Rhythm Management | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,403 | 1,405 | 1,337
Cardiac Rhythm Management | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 876 | 813 | 763
Electrophysiology (EP) | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,904 | 800 | 585
Electrophysiology (EP) | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,256 | 370 | 275
Electrophysiology (EP) | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 648 | 430 | 310
Watchman | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,516 | 1,274 | 1,019
Watchman | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,371 | 1,155 | 915
Watchman | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 145 | 119 | 103
Global Cardiology Reporting Unit | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 8,344 | 6,709 | 5,932
Global Cardiology Reporting Unit | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 4,855 | 3,673 | 3,271
Global Cardiology Reporting Unit | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 3,490 | 3,036 | 2,662
Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 0 | 0 | (60)
Other | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 0 | 0 | 0
Other | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 0 | 0 | 0
MedSurg | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 5,993 | 5,422 | 4,911
MedSurg | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 4,054 | 3,617 | 3,312
MedSurg | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,939 | 1,805 | 1,599
Cardiovascular | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 10,755 | 8,819 | 7,831
Cardiovascular | UNITED STATES | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 6,156 | 4,808 | 4,319
Cardiovascular | Non-US [Member] | Operating Segments |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | $ 4,599 | $ 4,011 | $ 3,512

X
- References No definition available. + Details
Name: | us-gaap_ChangeInContractWithCustomerLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_ContractWithCustomerLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_EMEAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AsiaPacificMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=bsx_LatinAmericaandCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=bsx_EmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=bsx_USExcludingOtherNetSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_WatchmanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |